A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 (MACS study)
Tomohiro Kadota, Ryo Nishikawa(Kanazawa Hospital), Takashi Komori(Tokyo Metropolitan Neurological Hospital), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Junki Mizusawa(Japan Clinical Cancer Research Organization), Hiroshi Igaki(National Cancer Centre Japan), Manabu Kinoshita(Brigham and Women's Hospital), Koichi Ichimura(Hiroshima City Asa Citizens Hospital), Yoshitaka Narita(Unknown), Hiroshi Katayama(National Cancer Center), Toshihiro Kumabe(Kitasato University), Ryuta Saito(Nagoya University)
Cited by 14
Related Papers
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
|Nature Genetics|2009|788
Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood–brain barrier disruption
|Proceedings of the National Academy of Sciences|2006|648
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53
|Nature Genetics|2003|583